沙利度胺治疗多发性骨髓瘤

Thalidomide in the treatment of multiple myeloma.

作者信息

Rajkumar S V

机构信息

Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

出版信息

Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8. doi: 10.1586/14737140.1.1.20.

DOI:10.1586/14737140.1.1.20

PMID:12113124

Abstract

Thalidomide--banned from clinical use in the 1960s because of severe teratogenicity--is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma. Several clinical trials have determined that thalidomide is active in 25-35% of patients with relapsed myeloma. The role of thalidomide in early-stage myeloma is being actively investigated. Thalidomide has antiangiogenic and immunomodulatory properties and is an effective inhibitor of TNF-alpha. However, the mechanism of its action in myeloma remains unclear. Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma.

摘要

沙利度胺——因其严重的致畸性在20世纪60年代被禁止临床使用——如今作为一种治疗复发难治性多发性骨髓瘤的有效药物重新应用于临床实践。多项临床试验已确定沙利度胺对25%至35%的复发骨髓瘤患者有效。沙利度胺在早期骨髓瘤中的作用正在积极研究中。沙利度胺具有抗血管生成和免疫调节特性，是肿瘤坏死因子-α的有效抑制剂。然而，其在骨髓瘤中的作用机制仍不清楚。沙利度胺的主要毒性包括便秘、镇静、皮疹、疲劳和周围神经病变。本文总结了沙利度胺在多发性骨髓瘤中的现状。